当前位置:首页 - 行情中心 - 南模生物(688265) - 财务分析 - 利润表

南模生物

(688265)

  

流通市值:25.13亿  总市值:25.13亿
流通股本:7796.35万   总股本:7796.35万

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入88,396,140.55381,239,513.99264,848,483.4176,851,264.77
营业收入88,396,140.55381,239,513.99264,848,483.4176,851,264.77
二、营业总成本94,524,575.57398,788,336.81296,662,616.31195,649,343.42
营业成本45,096,068.5207,247,055.01149,290,455.6798,814,037.62
税金及附加663,981.163,863,669.482,202,404.241,827,354.74
销售费用15,287,149.0658,012,150.2745,627,932.2730,150,216.02
管理费用13,094,716.1553,595,460.7539,826,209.0624,660,099.43
研发费用19,755,542.2774,981,116.5857,232,634.7638,804,681.16
财务费用627,118.431,088,884.722,482,980.311,392,954.45
其中:利息费用718,427.153,801,010.433,054,903.992,165,704.27
其中:利息收入599,033.921,834,994.791,191,560.45-759,110.91
加:公允价值变动收益5,422,190.0319,301,458.6915,840,269.9210,434,071.97
加:投资收益104,414.021,041,919.05714,176.57714,176.57
资产处置收益-20,207.24-7,835.19-7,835.19
资产减值损失(新)-1,288,538.88-844,076.86-1,332,490.25-1,453,100.06
信用减值损失(新)-2,431,685.83-4,746,341.63-7,741,601.29-6,369,088.02
其他收益2,082,310.255,563,627.943,532,676.12,361,596.39
营业利润平衡项目0000
四、营业利润-2,239,745.432,787,971.61-20,808,937.05-13,118,256.99
加:营业外收入-57,335.3945,912.9945,912.99
减:营业外支出50,100116,677.4155,474.7955,128.74
利润总额平衡项目0000
五、利润总额-2,289,845.432,728,629.59-20,818,498.85-13,127,472.74
减:所得税费用-1,323,026.38-3,766,874.46-5,623,142.6-3,983,899.52
六、净利润-966,819.056,495,504.05-15,195,356.25-9,143,573.22
持续经营净利润-966,819.056,495,504.05-15,195,356.25-9,143,573.22
归属于母公司股东的净利润-966,819.056,495,504.05-15,195,356.25-9,143,573.22
(一)基本每股收益-0.010.08-0.2-0.12
(二)稀释每股收益-0.010.08-0.2-0.12
八、其他综合收益-43,265.75341,360.49-227,518.56174,186.54
归属于母公司股东的其他综合收益-43,265.75341,360.49-227,518.56174,186.54
九、综合收益总额-1,010,084.86,836,864.54-15,422,874.81-8,969,386.68
归属于母公司股东的综合收益总额-1,010,084.86,836,864.54-15,422,874.81-8,969,386.68
公告日期2025-04-292025-04-292024-10-312024-08-29
审计意见(境内)标准无保留意见
TOP↑